Aggressive antihypertensive treatment, particularly with renin-angiotensin system inhibitors, is crucial for renoprotection and mitigating vascular complications in diabetic patients.
Answers are grounded in this paper and cite their sources.
Supports RAS inhibition for renoprotection in diabetic nephropathy; leaves open need for updated RCTs in contemporary populations.
Hypertension is often associated clinically with diabetes either as part of the insulin resistance syndrome or as a manifestation of renal disease. Elevated systemic blood pressure accelerates the progression of both microvascular and macrovascular complications in diabetes. Agents that interrupt the renin-angiotensin system confer renoprotection via a range of hemodynamic and nonhemodynamic mechanisms. Recent clinical trials confirm that these agents confer renoprotection in type 1 and type 2 diabetic patients with early or advanced renal disease. Hypertension also appears to accelerate vascular and cardiac abnormalities in diabetes, including increased atherosclerosis, arterial stiffness, left ventricular hypertrophy and diastolic dysfunction. A number of recently published and ongoing trials are exploring the role of aggressive antihypertensive treatment with a range of antihypertensive drugs in diabetic subjects at risk of or with macrovascular disease.
No takes yet. Share an insight, caveat, or question.
Jandeleit‐Dahm et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: